Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBW-3220 phase I/II study in relapsed or refractory mature B-cell lymphoma
ChiCTR2200062537Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HBW-3220 in mature B-cell lymphoma and B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: Maximum tolerated dose, Dose-limiting toxicity and 1 more. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
HBW-3220
03
Conditions
mature B-cell lymphomaB-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on ChiCTR2200062537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062537.